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Abstract 
Protein kinase AMP-activated catalytic subunit 
alpha 1 (PRKAA1), also known as AMPK α1, is an 
energy sensor that plays a key role in the regulation 
of cellular energy metabolism. AMPK α1 is the 
catalytic subunit of the heterotrimeric AMPK protein 
with a length of 548 amino acids. A key switch to 
activate this protein is an alteration in the AMP/ATP 
ratio.  
The protein is dysregulated in several human 
diseases including diabetes and metabolic syndrome, 
cardiovascular diseases, neurodegenerative diseases 
and many cancer types (Steinberg and Kemp, 2009). 
Two isoforms of AMPK exist including AMPK α1 
and AMPK α2; however, discrimination between 
these isoforms for their involvement in certain 
diseases is currently not possible. 
Keywords 
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Identity 
Other names: AMPK, AMPKa1, AMPK1, AMPK 
Alpha 1 
HGNC (Hugo): PRKAA1 
Location: 5p13.1 
Local order 
Starts at 40759379 and ends at 40798195 bp from 
pter (according to hg38-Dec_2013) 
DNA/RNA 
Detailed genomic configuration of human PRKAA1 
gene can be found in 
https://www.ncbi.nlm.nih.gov/gene/5562. 
Description 
The human AMPK α1 gene is located on 5p13.1 and 
spans about 39 kb. It contains 12 exons and 2 
promoters named as PRKAA1_1 and PRKAA1_2. 
The gene has 3 isoforms named as PRKAA1_001, 
PRKAA1_002 and PRKAA1_003. 
Transcription 
The human AMPK α1 gene has 9 transcripts: 
PRKAA1-201 (1134 bp), PRKAA1-202 (1918 bp), 
PRKAA1-204 (5088 bp) that code for a protein. 
PRKAA1-203 (425 bp), PRKAA1-205 (919 bp), 
PRKAA1-206 (1082 bp), PRKAA1-207 (692 bp), 
PRKAA1-208 (668 bp) and PRKAA1-209 (436 bp) 
have retained introns. It also has 7 paralogues and 97 
orthologues. 
Pseudogene 
PRKAA1 has one hypothetical pseudogene titled as 




AMPK α1 is the catalytic subunit of the 
heterotrimeric AMPK protein with a length of 548 
amino acids.  
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Figure 1.  Domains of AMPK-α1. (AID: UBA-like Autoinhibitory Domain) 
 
In response to an increase in the AMP/ATP ratio, 
AMPK gets activated. AMP binds to the non-
catalytic gamma subunit of the AMPK protein and 
induces phosphorylation of Thr-183 (Lizcano et al., 
2004). This residue is present in the T-loop region of 
the catalytic subunit, AMPK α1 (Bright et al., 2009).  
There are several known AMPK kinases 
(AMPKKs). STK11 (LKB1), complexed with 
STRADA and CAB39 (MO25), is the major 
upstream regulator of the AMPK, which 
phosphorylates the AMP bound protein (Shackelford 
and Shaw, 2009). Ca2+/calmodulin-dependent 
protein kinase kinase β (CAMKK2 or CaMKKβ) is 
also known to be an upstream kinase of AMPK 
(Sundararaman et al., 2016). TGF-beta-activated 
kinase-1 (MAP3K7 or TAK1) may also 
phosphorylate AMPK α or at least play a role in its 
activation as loss of TAK1 leads to impaired AMPK 
activation (Xie et al., 2006).  
The AMPK α1 protein consists of several domains 
(Figure 1). The N-terminal kinase domain carries out 
the serine/threonine kinase function. The C-terminus 
regulatory domain contains an α-RIM sensor loop 
and a β-subunit interaction domain (Crute et al., 
1998). A UBA-like auto-inhibitory domain (AID) is 
present between the α-RIM sensor loop and the 
kinase domain. AID is required for allosteric 
regulation via AMP. Absence of this inhibitory 
region renders the protein independent of AMP but 
still requires phosphorylation of the activation loop 
(Crute et al., 1998). 
Expression 
AMPK α1 is widely expressed across many tissues 
such as brain, heart, kidney, liver and lung (Stapleton 
et al., 1996). 
Localisation 
It is primarily localized in the cytoplasm, and with 
HUVEC cells it was shown that AMPK α1 localizes 
exclusively in the cytoskeleton (Pinter et al., 2012). 
Function 
AMPK α1, in its active form, phosphorylates many 
downstream proteins. These phosphorylated target 
proteins of AMPK regulate metabolism, autophagy, 
cell growth and proliferation, and cell polarity 
(Hardie, 2011). AMPK exists as an obligate 
heterotrimer in cells (Mihaylova and Shaw, 2011), 
and all the functions that will be mentioned in this 
section are carried out by the α1 subunit in this 
obligate heterotrimer complex. 
Cellular Metabolism 
AMPK is activated when there is energy stress in the 
cell manifested by an increase in the AMP/ATP 
ratio. In response to this stress, AMPK activates 
catabolic pathways while inhibiting anabolic 
pathways. 
Glycolysis 
One of the key catabolic pathways for energy 
generation, glycolysis, is upregulated through 
AMPK signalling. In order increase glucose uptake 
to the cell, AMPK activates (induces translocation, 
short term response) and increases protein 
expression (longer term response) of SLC2A1 
(GLUT1) and SLC2A4 (GLUT4) (Fryer et al., 
2002). Also, 6-phosphofructo-2-kinase (PFKFB3 or 
PFK-2) gets phosphorylated and activated by AMPK 
which enhances glycolysis (Marsin et al., 2000). 
Glycogen synthesis (anabolic pathway) is inhibited 
by the phosphorylation of glycogen synthase. 
Gluconeogenesis 
Anabolic pathways such as gluconeogenesis that 
enhance glucose levels are inhibited by repression of 
transcripts that encode for gluconeogenesis 
enzymes. CRTC2, coactivator of the cyclic AMP 
response element-binding protein CREB, gets 
phosphorylated and inhibited (excluded from the 
nucleus) by AMPK. This leads to disruption of 
CREB-CRTC2 complex and inhibition of CREB-
dependent gluconeogenesis (Lee et al., 2010). 
Transcription of mRNAs encoding glucose-6-
phosphatase and phosphoenolpyruvate 
carboxykinase are inhibited via this mechanism. 
Also, class IIA histones, which can activate the 
FOXO family of transcription factors via HDAC3 
recruitment, gets phosphorylated and excluded from 
the nucleus. This decrease in activity of FOXO 
family of transcription factors leads to reduced 
expression of gluconeogenesis genes (Mihaylova et 
al., 2011). 
Lipid Metabolism 
In AMPK activated cells, fatty acid uptake is 
increased by translocation of fatty acid translocase, 
CD36 (FAT), to the cellular membrane (Bonen et al., 
2007). Meanwhile, acetyl-CoA carboxylase 
(ACACA ACC1), which catalyses the rate-limiting 
step of fatty acid synthesis (Hofbauer et al., 2014), 
gets phosphorylated and this phosphorylation 
inhibits the enzymatic activity of ACC1.  
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Figure 2.  Functions of AMPK 
 
Along with CD36 (FAT) translocation to the 
membrane, ACACB (ACC2) is also inhibited which 
leads to increased fatty acid uptake into 
mitochondria due to decreased amounts of malonyl-
CoA in the cell (Merrill et al., 1997). 
Protein Synthesis 
Synthesis of proteins is an enormous energy 
consuming process for the cells. MTOR, in its active 
form, promotes cell proliferation and protein 
synthesis. Activated AMPK inhibits mTOR via 
phosphorylation of upstream regulator TSC2 (Huang 
and Manning, 2008) and its subunit RPTOR (Raptor) 
(Gwinn et al., 2008). Also, eukaryotic elongation 
factor 2 ( EEF2) is required for the elongation of 
translation in eukaryotes. EEF2 kinase gets activated 
by AMPK which inhibits EEF2 via phosphorylation, 
resulting in inhibition of protein synthesis (Horman 
et al., 2002).  
Autophagy  
Excess or dysfunctional organelles get "eaten up" by 
the cell over time, this process is called autophagy 
and it can give cells the advantage of recycling 
important nutrients, especially during starvation. It is 
known that mTORc1 inhibits autophagy via 
inhibition of ULK1 (Chan, 2009), and AMPK 
downregulates mTORc1 via phosphorylation of 
TSC2 and Raptor. This was thought to be the main 
mechanism by which AMPK activates autophagy. 
Recently, it was found that initiator of autophagy, the 
ULK1 protein kinase, directly interacts with AMPK, 
and gets phosphorylated and activated by AMPK 
(Roach, 2011). 
Cell Growth and Proliferation 
AMPK can act as a metabolic checkpoint via 
inhibition of cellular growth when energy status in 
the cell is compromised (Mihaylova and Shaw, 
2011).  
Processes of cellular growth and proliferation 
require many events to take place in the cell such as 
protein and lipid synthesis. As mentioned above, 
AMPK can decrease the synthesis of proteins and 
subsequently cell proliferation through the inhibition 
of mTORc1. mTORc1 also controls lipid 
biosynthesis via a transcription factor named as 
sterol regulatory element-binding protein-1, 
SREBF1 (SREBP-1) (Laplante and Sabatini, 2009). 
SREBP-1 targets lipogenic genes such as ACC 
(Brown et al., 2007); fatty acid synthase, FASN 
(Jung et al., 2012); and stearoyl-CoA desaturase 1, 
SCD (Mauvoisin et al., 2007). mTORc1 inhibition 
by AMPK along with the previously mentioned 
inhibition of ACC1 leads to decreased lipid synthesis 
in the cell. Other than metabolic effects, AMPK also 
activates checkpoint regulators such as TP53 via 
inactivation of SIRT1 (Sirtuin 1) (Lee et al., 2012) 
and phosphorylation at Ser-15 (Jones et al., 2005), as 
well as CDKN1B (cyclin-dependent kinase inhibitor 
p27(Kip1)) via phosphorylation at Thr198 (Liang et 
al., 2007). 
Cell Polarity 
LKB1-null and AMPK-null Drosophila models 
show lethal phenotypes with severe defects in cell 
polarity and mitosis (Lee at al., 2007). AMPK 
activation was reported to rescue LKB1-null 
phenotype while non-muscle myosin regulatory light 
chain (MRLC) phopshomimetic mutants rescued 
AMPK-null models (Lee at al., 2007). However, 
another study reported that in mammalian MDCK 
cells, AMPK activation did not change 
phosphorylation of MRLC, rather AFDN (afadin) 
was identified as AMPK substrate for 
phosphorylation (Zhang et al., 2011). Activation via 
AMPK leads to deposition of junction components 
in the cellular membrane.  
PRKAA1 (protein kinase AMP-activated catalytic subunit 
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The microtubule plus-end-tracking protein CLIP1 
(CLIP-170) is activated via phosphorylation by 
AMPK. CLIP-170 phosphorylation is required for 
microtubule dynamics and the regulation of 
directional cell migration (Nakano et al., 2010).  The 
same study reported that inhibition of AMPK leads 
to accumulation of CLIP-170 at microtubule tips and 
slower tubulin polymerization (Nakano et al., 2010). 
Thus, AMPK also controls microtubule dynamics 
through CLIP-170 phosphorylation.  
Homology 
AMPK α1, with its kinase and regulatory domains, 
is a very well conserved protein.  
Implicated in 
Top note 
AMPK, a central switch determining the AMP/ATP 
ratio, is dysregulated in several human diseases 
including diabetes and metabolic syndrome, 
cardiovascular diseases, neurodegenerative diseases 
and several different cancer types (Steinberg and 
Kemp, 2009). Both isoforms of AMPK: AMPK α1 
and AMPK α2 may be involved in these diseases. 
AMPK was shown to negatively regulate the 
Warburg effect in genetically ablated AMPK- α1 
cancer models in vivo (Faubert et al., 2013); 
therefore, AMPK can be classified as tumour 
suppressor although there is also evidence of 
negative regulation of AMPK by tumour suppressors 
or proto-oncogenes (Li et al., 2017; Yan et al., 2014). 
Huntington's Disease 
Huntington's disease (HD) is a neurodegenerative 
disease where the AMPKα1 isoform is known to be 
activated in the caudate nucleus and frontal cortex of 
humans.  
Activated AMPKα1 was reported to accumulate in 
the nuclei in these specific regions of the brain of HD 
patients. Brain atrophy, facilitated neuronal loss and 
increased aggregation of huntingtin (HTT) protein 
was observed in a transgenic mouse model with 
Huntington's disease, which had overactivated 
AMPKα1. Ameliorated cell death and down-
regulation of BCL2 (by mutant Htt) was achieved by 
prevention of nuclear translocation or inactivation of 
AMPK- α1 (Ju et al., 2011). 
Prostate Cancer 
In prostate cancer, the androgen receptor (AR) plays 
a critical role in the regulation of cell proliferation 
and death. There is evidence that AR related 
progression of prostate cancer correlates with 
activated AMPK levels.  
Androgen-mediated AMPK activity was reported to 
increase the levels of intracellular ATP and 
PPARGC1A (peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α))-
mediated mitochondrial biogenesis.  
PRKAA1 (protein kinase AMP-activated catalytic subunit 
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siRNA-mediated knockdown of AMPKα1, the 
predominant isoform correlated with poor prognosis 
in prostate cancer patients, in LNCaP and YCaP 
human prostate cancer cells reduced the levels of 
PGC-1α, which is overexpressed in clinical cancer 
samples (Tennakoon et al., 2015).  
5- ATIC (Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR)), is an AMPK agonist that 
enhances phosphorylation of AMPK- α1 at Thr-172 
and its downstream target ACC at Ser-79. Prostate 
cancer cell lines infected with lentiviral shRNA 
against AMPK- α1 were shown to almost block 
AICAR-induced AMPK phosphorylation. AICAR-
induced cytotoxicity in prostate cancer cells was 
slightly more potent than other AMPK activators 
such as A-769662 and Compound 13. It has been 
suggested that AICAR-induced cytotoxicity was not 
dependent of AMPK activation but might play a pro-
survival role in prostate cancer cells (Guo et al., 
2016). 
Colorectal Cancer 
The current literature suggests that activation of 
AMPK through natural compounds such as 
berberine, epigallocatechin gallate or quercetin can 
enhance apoptosis through the upregulation and 
phosphorylation of TP53 at Ser15, inhibition of 
COX-2 and mitigation of inflammation as well as 
delay in cell cycle progression (Sun and Xhu, 2017). 
AMPKα1 is expressed in almost all colorectal cancer 
cell lines; however, AMPKα2 expression is limited 
to some cell lines. Although siRNA-mediated 
AMPKα1 knock down has no effect on cell death, 
AMPKα2 depletion was shown to induce cell death 
in both HCT116 and SW480 cell lines. A 
competitive inhibitor of AMPK, 5'-hydroxy-
staurosporine, was identified by FUSION 
(Functional Signature Ontology), a method to screen 
natural compounds for the identification of AMPK 
inhibitors. Colorectal cancer cell lines were reported 
to be more sensitive to 5'-hydroxy-staurosporine 
compared to non-transformed human colon 
epithelial cells (Das et al., 2018).  
Another study suggests that Icaritin (a flavonoid 
with anti-tumorigenic activity) was reported to 
induce AMPK signaling in colorectal cancer (CRC) 
and it also activates autophagy. AMPK-α1 
knockdown (shRNA or siRNA mediated) inhibited 
icaritin-activated autophagy but increased cell death 
in CRC both in vitro and in vivo (Zhou et al., 2017). 
Type 2 Diabetes 
AMPK is known to be dysregulated in patients with 
metabolic syndrome or type 2 Diabetes. Activation 
of AMPK either through the alteration of the 
AMP/ATP ratio of by pharmacological agonists can 
improve insulin sensitivity and metabolic health. In 
the primary metabolic tissues such as skeletal 
muscles, cardiac muscle, liver and adipose tissue, 
activation of AMPK was reported to stimulate 
glucose uptake, fatty acid oxidation, glucose 
transporter type (GLUT)4 translocation (in skeletal 
muscles), mitochondrial biogenesis, while inhibiting 
gluconeogenesis (in the liver) as well as protein, 
fatty acid, cholesterol and glycogen synthesis. 
AMPK is also known to inhibit insulin secretion 
from pancreatic β-cells and can signals to enhance 
food intake in the hypothalamus. All of these are 
beneficial for Type 2 diabetes (Coughlan et al., 
2014). In an animal model of type 2 diabetes 
established by the Otsuka Long-Evans Tokushima 
Fatty (OLETF) rat, which had chronic and slowly 
progressive hyperglycemia and hyperlipidemia, 
overexpression of adenoviral-mediated AMPK-α1 
showed a modest decrease in blood glucose level 
although glucose tolerance was not recovered 
completely.  
Moreover, plasma triglyceride level and hepatic 
triglyceride contents were also slightly decreased 
(Seo et al., 2009). 
Aging 
Dietary restriction (DR), a process of reduced food 
intake without inducing malnutrition, elicits a low-
energy state in the organism, which in turn delays 
ageing in species ranging from yeast to primates 
through the activation of nutrient-sensing pathways 
such as AMPK (Burkewitz et al, 2014). For example, 
feeding C. elegans 2-deoxy-D glucose leading to the 
inhibition of glycolysis and glucose metabolism 
increased the lifespan of the worms in an aak-2 
(catalytic subunit of AMPK in C. elegans) dependent 
manner (Schulz et al., 2007). In rat EDL (extensor 
digitorum longus) muscle, AMPK-α1 protein level 
was reported to be higher in older rats compared to 
younger rats. On the other hand, young rats showed 
higher expression of AMPK-α2 proteins than the 
older group. EDL cells treated with AICAR showed 
increased AMPK-α2 activity in both age groups, 
while AMPK-α1 activity was increased only in the 
young group. AMPK-α1 activity was not changed in 
the EDL muscles that were stimulated by high 
frequency electrical in the young group (Thompson 
et al., 2009). 
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